NEW YORK (TheStreet) -- CHANGE IN RATINGS
( AMLN) downgraded at BMO from Market Perform to Underperform. $12 price target. LAR approval could be delayed until late 2011, as the FDA will likely request more clinical data.
downgraded at BofA/Merrill to Neutral from Buy as valuation and fundamentals are less compelling. $35 price target.
upgraded at UBS from Sell to Neutral. $68 price target. Estimates also boosted, because of a higher delivery forecast.
downgraded at Kaufman from Hold to Sell. Valuation call, as the stock is up 16% since the recent CEO change. $11 price target.
upgraded at BofA/Merrill to Buy from Neutral on expectations that 2011 earnings will beat expectations. Estimates raised through 2012. Price target boosted to $42 from $33.
rated new Equal-weight at Morgan Stanley. Core fruit business has limited upside potential from current levels.
upgraded at Morgan Keegan from Market Perform to Outperform. Company has strong earnings leverage as volumes recover.
upgraded at UBS from Neutral to Buy. $62 price target. Valuation call, as the company has been showing strong volume and cash flow growth.
( LSTZA) rated new Buy at UBS. $65 price target. Stock is overly discounting future programming costs and sports and attractive 10% free cash flow yield.
Madison Square Garden
rated new Neutral at UBS. Coverage of MSG was started with a Neutral rating. $22 price target. Company will spend more to upgrade its arena in 2011. Valuation also appears high.
upgraded at Goldman from Sell to Neutral. Estimates also raised, as the new Oasis and Solstice ships are showing a significant relative premium. $27 price target.
upgraded at UBS from Sell to Neutral. $22 price target. Higher deliveries should drive earnings.
STOCK COMMENTS / EPS CHANGES
estimates tweaked at Credit Suisse. ACN 2010 and 2011 EPS estimates lowered to $2.65 and $2.99, respectively. Currency drags. Maintain Outperform rating and $55 target.
target, estimates raised at BofA/Merrill. AIMC price target increased by $2 to $15 on higher earnings estimates. 2010 and 2011 EPS estimates raised to $0.85 and $1.15, respectively. Maintain Buy.
Alon USA Energy
target, estimate cut at Barclays. ALJ price target trimmed by a dollar to $6 on weak 4Q09 results. 2010 EPS estimate lowered to -$1.85. Underweight rating.
target raised at FBR to $90. Company has very attractive exploration opportunities. Outperform rating.
numbers lowered at Goldman. BJ estimates were cut through 2011. Company is ramping up internal investments. Sell rating and new $31 price target.
estimates lowered at Goldman through 2012. Gross margin is facing more difficult comparisons. Neutral rating and $61 price target.
estimates, target increased at Goldman. ENR estimates were boosted through 2012. New Schick and Edge razors should drive organic sales growth. Neutral rating and new $68 price target.
price target boosted at Credit Suisse. FNSR price target raised to $13.50 from $11 after solid 3Q10 results. Neutral rating. 2010 and 2011 EPS estimates set at 52 cents and 90 cents, respectively.
( JOYG) estimates, target boosted at UBS. Shares of HSY now seen reaching $42. Estimates also raised, as the new analyst believes that the company is gaining brand momentum. Neutral rating.
( JOYG) estimate tweaked at Barclays. JOYG 2010 EPS estimate inched up to 3.10, 2011 maintained at $3.95. Maintain Overweight rating and $67 price target.
( JOYG) estimates, target upped at Goldman. Shares of JOYG now seen reaching $64. Estimates also boosted, given higher equipment production. Neutral rating.
estimates upped at Morgan Stanley through 2011. Company is being less aggressive with pricing and gross margin should stabilize. Equal-weight rating.
Las Vegas Sands
numbers cut at Goldman through 2011. Company seeing lower profits in Las Vegas properties. Neutral rating and new $17 price target.
( ME) price target raised at Credit Suisse by a dollar to $18 as it continues to build its onshore asset base. 2010 and 2011 EPS estimates changed to -$0.29 and $0.13, respectively. Maintain Outperform rating.
numbers increased at Goldman. Shares of NYX now seen reaching $32. Estimates also boosted, as management is cutting costs and should be able to generate incremental revenue growth.
price target higher at Credit Suisse. PETM price target surged to $35 from $29. PetSmart is one of our most attractive manes going forward, Credit Suisse said. 2011 and 2012 EPS estimates raised to $1.85 and $2.13, respectively. Maintain Outperform rating.
estimates, target raised at Goldman. Shares of PETM now seen reaching $32. Estimates also upped, to reflect an active share repurchase program. Neutral rating.
target lowered at Citigroup. Shares of SPLS now seen reaching $26. Stock could receive a more conservative multiple, following the company's lower earnings guidance. Buy rating.
price target boosted at BofA/Merrill to $57 from $55 as share buybacks resume. 2011 EPS estimate bumped up to $6.75. Reiterate Buy.
price target higher at Thomas Weisel, to $32 from $30 on solid guidance. Maintain Overweight rating.
target, estimate raised at Barclays. URS price target increased a dollar to $53 on strong 2010 guidance. 2010 EPS estimate jumped 10 cents to $3.45. Equal Weight rating.
estimates, target increased at UBS. Shares of URS now seen reaching $51. Estimates also raised, to match the company's new guidance. Neutral rating.
This article was written by a staff member of TheStreet.com.